1. Home
  2. JBL vs BIIB Comparison

JBL vs BIIB Comparison

Compare JBL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jabil Inc.

JBL

Jabil Inc.

HOLD

Current Price

$220.24

Market Cap

21.7B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.61

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBL
BIIB
Founded
1966
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7B
24.2B
IPO Year
1993
1991

Fundamental Metrics

Financial Performance
Metric
JBL
BIIB
Price
$220.24
$181.61
Analyst Decision
Strong Buy
Buy
Analyst Count
9
23
Target Price
$228.78
$176.48
AVG Volume (30 Days)
1.1M
1.9M
Earning Date
12-17-2025
10-30-2025
Dividend Yield
0.15%
N/A
EPS Growth
N/A
N/A
EPS
5.92
10.97
Revenue
$29,802,000,000.00
$10,065,900,000.00
Revenue This Year
$6.68
$3.61
Revenue Next Year
$6.07
N/A
P/E Ratio
$37.17
$16.52
Revenue Growth
3.18
4.77
52 Week Low
$108.66
$110.04
52 Week High
$237.14
$185.17

Technical Indicators

Market Signals
Indicator
JBL
BIIB
Relative Strength Index (RSI) 61.75 72.92
Support Level $209.40 $174.53
Resistance Level $206.56 $182.94
Average True Range (ATR) 7.01 5.22
MACD 2.16 0.25
Stochastic Oscillator 92.92 83.54

Price Performance

Historical Comparison
JBL
BIIB

About JBL Jabil Inc.

Jabil Inc is a United States-based company engaged in providing manufacturing services and solutions. It provides comprehensive electronics design, production and product management services to companies in various industries and end markets.The Company derives its revenue from providing comprehensive electronics design, production and product management services. It operates in two segments. The Electronics Manufacturing Services (EMS) segment, which is the key revenue driver, is focused on leveraging IT, supply chain design and engineering, technologies largely centered on core electronics. The Diversified Manufacturing Services (DMS) segment is focused on providing engineering solutions, with an emphasis on material sciences, technologies, and healthcare.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: